mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus.
14 Luglio 2021
|By TPM
Gelsomino F, Casadei-Gardini A, Caputo F, Rossi G, Bertolini F, Petrachi T, Spallanzani A, Pettorelli E, Kaleci S, Luppi G. Cancers (Basel). 2020 May 10;12(5):1201. doi: 10.3390/cancers12051201.PMID: 32397669
Read Abstract